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ABSTRACT  
Our objective was to investigate the impact of EPA versus DHA, on arterial stiffness and reactivity, 
and underlying mechanisms (with a focus on plasma oxylipins), in the postprandial state.  
In a 3-arm cross-over acute test meal trial men (n=26, 35-55y) at increased CVD risk, received a high 
fat (42.4g) test meal providing 4.16 g of EPA or DHA or control oil in random order. At 0 h and 4 h, 
blood samples were collected to quantify plasma fatty acids, LCn-3PUFAs derived oxylipins, nitrite 
and hydrogen sulfide and serum lipids and glucose. Vascular function was assessed using blood 
pressure, Reactive Hyperaemia Index (RHI), Pulse Wave Velocity and Augmentation Index (AIx).  
The DHA-rich oil significantly reduced AIx by 13% (P=0.047) with the decrease following EPA-rich 
oil intervention not reaching statistical significance. Both interventions increased EPA and DHA 
derived oxylipins in the acute postprandial state, with an (1.3 fold) increase in 19,20-DiHDPA evident 
after DHA intervention (P < 0.001).  
In conclusion, a single dose of DHA significantly improved postprandial arterial stiffness as assessed 
by AIx, which if sustained would be associated with a significant decrease in CVD risk. The observed 
increases in oxylipins provide a mechanistic insight for the AIx effect.  
 
 
Supplementary keywords: augmentation index, blood pressure, fish oil, hydrogen sulfide, 
lipidomics, nitric oxide, nutrition, omega-3 fatty acids, pulse wave velocity.   
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INTRODUCTION 
An impact on arterial stiffness and compliance, associated with reduced blood pressure (1-4), is 
thought to be a significant contributor to the lower CVD risk associated with increased long chain n-3 
PUFA (LCn-3PUFA, EPA plus DHA) intake and status (4-6). 
In randomized controlled trials (RCTs) conducted to date, vascular function is typically measured in 
the fasting non-challenged state. Given that adults following Westernized dietary patterns typically 
spend 16-18h per day in the postprandial state, and that a postprandial phenotype characterized by an 
exaggerated lipaemia and glycemia and inflammatory and oxidative stress is associated with vascular 
dysfunction (7), the postprandial vascular response is likely to be a more significant and 
discriminating marker of CVD risk. However, the impact of dietary factors and meal composition on 
acute postprandial vascular function is poorly understood.  
Increasing the total fat content of a test meal reduces both cardiac and peripheral postprandial vascular 
reactivity (7) and a small number of studies providing EPA plus DHA in the test meal have reported a 
positive effect of fish oil on vascular tone over 2-8h (8-12). Although rarely considered, variability in 
the EPA and DHA ratio of the n-3 PUFA (fish or fish oil) source used in RCTs is likely to be a major 
determinant of the apparent inconsistency in findings reported. 
A limited number of chronic interventions that measured fasting vascular function, indicate that DHA 
has a greater beneficial effect on vascular function than EPA (4). However, with the exception of a 
single trial that examined relative impact on the cardiovascular hemodynamic responses to exercise 
(11), no study has directly compared the effects of EPA- versus DHA-rich oils on the postprandial 
response.  
Identification of the most bioactive LCn-3PUFA or EPA: DHA ratio on ‘health’ end-points is 
important in order to refine current dietary recommendations and allow the stratification of 
intervention to suit an individual’s phenotype. Furthermore, with the emergence of non-fish sources of 
these fatty acids, such as separate EPA and DHA produced by marine microalga or in transgenic seed 
oils, and the availability of EPA and DHA concentrates, all with potentially bespoke EPA and DHA 
content, information on their relative bioactivity is needed in order to inform these production systems 
(13, 14).  
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The primary aim of this double-blind, placebo-controlled acute test meal study was to compare the 
impact of EPA vs. DHA on postprandial (4 h) vascular function as assessed by blood pressure (BP), 
Pulse Wave Velocity (PWV), Reactive Hyperaemia Index (RHI) and Augmentation Index (AIx). 
Underlying molecular mechanisms were investigated by quantifying potential circulating mediators of 
vascular function including nitrite (as a biomarker of nitric oxide (NO), hydrogen sulfide (H2S) and 
LCn-3PUFA hydroxy, epoxide and thiol metabolites. Although shown to be potent modulators of 
vascular tone in cell, animal and human ex vivo studies (15, 16), the role of these compounds in 
modulating EPA- and DHA-induced changes in vascular function in humans is currently unknown.  
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MATERIALS AND METHODS  
This single-center dietary intervention study was conducted at the Norwich and Norfolk University 
Hospital (NNUH) Clinical Trials and Research Unit, at the University of East Anglia, between 
September 2012 and September 2013. All participants provided informed consent prior to 
commencing the study. It was conducted according to the guidelines described in the Declaration of 
Helsinki, and ethical clearance was provided by the English National Research Ethics Service, East of 
England Research Ethics Committee (reference 12/EE/0011). This trial was registered at 
clinicaltrials.gov (NCT01692431). 
Subjects 
Twenty six males between the ages of 35-55 y were recruited through local and targeted online 
advertisement. Volunteers were recruited if they possessing one or more of the following CVD risk 
factors: total cholesterol (TC)  6 mmol/L, HDL cholesterol (HDL-C)  1.0 mmol/L, systolic BP 
(SBP) > 140 mmHg, diastolic BP (DBP) > 90 mmHg, or waist circumference > 102 cm, which 
individually were associated with an aged-adjusted relative risk RR of CVD ≥ 1.5, as previously 
described by Wilson et al (17). Exclusion criteria included any clinically diagnosed disease, BP  ≥ 
160/100 mmHg, abnormal liver function or blood cell count, use of lipid lowering or insulin 
sensitizing medication, use of steroids or non-steroidal anti-inflammatory drugs including aspirin, 
antibiotics use or vaccinations within 3 months of enrolment into the study, use of dietary fish-oil or 
high dose of anti-oxidant vitamin supplements, habitual consumers of more than one portion (140g) of 
oily fish per week, heavy drinkers (> 30 units (240g) of alcohol per week), smokers or ex-smokers 
ceasing < 3 months before screening. 
Study protocol 
On the three separate study days at least 4 weeks apart, EPA-rich oil (ERO), DHA-rich oil (DRO) or 
control oil (CO) containing meals were consumed in random order. Treatment order for each 
participant was randomized by an independent researcher, who was not involved in the study design, 
data collection or data analysis. For three days prior to their clinical visits subjects were asked to 
follow a restricted diet which included avoidance of n-3 PUFA rich foods and nitrate-, nitrite-, 
sulphite- and sulphate-rich foods (Supplementary Table S1) in order to standardize plasma n-3 
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PUFA, NO and H2S status. Individuals were also asked to avoid alcohol or strenuous exercise in this 
three day period. The evening before their clinical visits, subjects were requested to consume a 
standard low fat meal (<10g of fat) which was provided. Adherence to the restrictions was assessed at 
each visit by questionnaire, and a 24 hour dietary recall. 
On the clinical visit, baseline (0 h) vascular and BP measures were taken along with a fasting (> 10 h) 
blood sample. Following the consumption of the test meal, which participants were requested to 
consume within a 5 minute period, the vascular and BP measures and blood sampling were repeated at 
4 h. The 4 h time point was selected to coincide with the predicted peak plasma lipaemia and EPA and 
DHA plasma concentrations following lipid consumption (7). 
Meal design 
Test meals were isocaloric (3128 kJ; 9.5% of energy as protein, 51.0% of energy as fat (42.4 g total 
fat), and 39.5% of energy as carbohydrate) and matched for taste, smell and appearance. They were 
composed of a high-fat chocolate flavored milkshake containing the test fats and a peppermint extract 
to mask the fish oils, accompanied by toasted white bread (73g) and a low fruit content jam (30g). In 
the control meal the milkshake was composed of 40 g of a 4:1 palm oil/soybean oil mixture, skimmed 
milk (150 g), chocolate flavored powder (15 g), skimmed milk powder (15 g) and 2 g of peppermint 
oil extract. In the ERO- and DRO- test meals, 6.94 g and 8.33 g of the palm oil/soybean oil mixture 
was replaced by ERO or DRO (Epax®, FMC Health and Nutrition, Sandvika, Norway, see 
Supplementary Table S2 for full fatty acid profile) to provide 4.16 g of EPA or DHA, respectively.  
Measures of blood pressure and vascular function 
All vascular measures were taken in a temperature controlled room following a 15 min rest period. BP 
was taken using an Omron 750 CP-II device (Omron, Milton Keynes, UK) in a supine position. 
Arterial stiffness and endothelial dependent reactive hyperemia were assessed using PWV and the 
Endopat RHI respectively. AIx, a measure of the enhancement of central aortic pressure by a reflected 
pulse wave, which is dependent on the vascular tone of resistance arteries, was also undertaken. 
RHI was measured by arterial tonometry using an Endopat device (Itamar Medical Ltd, Caesarea, 
Israel) as previously described (18). Measures were taken for 5 minutes at rest, 5 minutes during 
brachial artery occlusion and another 5 minutes subsequent to occlusion release. RHI was calculated 
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by expressing the mean amplitude of peripheral arterial tone post occlusion relative to those at 
baseline. Non-occlusion effects were corrected for by accounting for changes in tone in the control 
arm probes. The RHI measure was also taken a second time at the postprandial (4h) time point in 
response to 400mg of sub-lingual nitroglycerine (GTN) in order to assess an impact of treatment on 
NO independent vasodilation. 
A vicorder device (Skidmore Medical, Bristol, UK) was used for the measurement of the PWV and 
AIx as described previously (19, 20). In brief, measures of carotid-femoral PWV were taken via 
placement of a BP cuff at the level of the carotid and femoral artery. The distance between the two 
anatomical sites was measured in each individual in order to allow calculation of pulse wave 
propagation speed in m/s. For AIx the Vicorder cuff was positioned over the brachial artery and AIx 
established by analysis of the blood pressure wave form. Specifically, AIx was calculated by 
expressing augmentation pressure (the difference between blood pressure during occurrence of the 
anacrotic notch and maximum systolic blood pressure) as a percentage of total pulse pressure.  
All BP and vascular measures were taken in triplicate apart from the RHI and RHI*GTN measures, 
which due to the basis of the methodology and the recovery time needed to return to pre-measurement 
values, were measured only once. 
Serum/plasma lipids, glucose, nitrite and H2S 
Blood samples for lipid and glucose analyses were left to sit at room temperature for 30 min and 
centrifuged at 2100 RCF at 4°C for 10 min. Serum samples were stored at -80°C until analysis. Serum 
triacylglycerol (TG), TC, HDL-C, non-esterified fatty acid (NEFA) and glucose were measured on an 
ILab650 automated analyzer (Instrumentation Laboratory, Warrington, UK) with commercially 
available kits (Instrumentation Laboratory). 
Blood samples for nitrite and H2S quantification were drawn into ice cold lithium heparin 
Vacutainers® and centrifuged immediately at 2100RCF at 4°C for 10 minutes. The obtained plasma 
samples were snap frozen and immediately stored at -80°C until analysis. Plasma nitrite analysis was 
conducted by reduction of nitrite to NO with chemiluminescent detection of NO undertaken via 
reaction with O3- as previously described (21). H2S was measured by reverse-phase HPLC coupled 
 
 
8 
 
with fluorescence detection after derivatization with monobromobimane, following methodology 
detailed previously by Shen et al (22).  
Plasma fatty acid and oxylipin analysis 
For fatty acid analysis, total lipids (TL) were extracted and analyzed as described previously (23).  In 
brief, TL were extracted from 500µl of plasma using chloroform/ methanol (2:1, vol/ vol). Fatty acid 
methyl esters (FAMEs) of the total lipid fraction were obtained by acid-catalyzed transmethylation, 
using nonadecanoic acid (19:0) (5% of the total lipid analyzed), as an internal standard. FAMEs were 
then purified by thin layer chromatography (TLC) and analyzed by gas-liquid chromatography. 
Oxylipin analysis of plasma samples was carried out in the facilities of the Institute for Vascular 
Signalling (Frankfurt, Germany). Briefly, samples were spiked with the corresponding deuterated 
internal standards (Cayman Europe, Tallinn, Estonia) and lipid epoxide and diol derivatives were 
extracted twice into ethyl acetate (0.5 ml) and quantified using a Sciex API4000 mass spectrometer 
operating in the multiple reaction monitoring mode as previously described (24, 25).  
Statistical Analysis 
Unless otherwise stated, data are presented as means ± SEM. Sample size calculations were 
undertaken with a power of 0.80 to detect clinically relevant changes at the 5% significance level for 
Endopat, PWV and AIx. The primary outcome for the trial was the Endopat RHI index, with PWV and 
AIx as secondary outcomes. For Endopat, given a SD of 0.4 (26) a clinically relevant difference of 
0.25 between treatments would be detectable in 21 subjects per treatment group. For PWV, given a SD 
of 1.2m/sec (27), a clinically relevant difference of 1.5m/sec would be detectable with a sample size of 
11 participants per treatment group. For AIx, a clinically relevant 4% decrease in AIx would be 
detectable in a population of 13 individuals, assuming a population SD of 5% in AIx. We aimed to 
recruit 26 participants. This number was chosen to allow for a potential drop-out rate of 15% and to 
provide a minimum of 22 participants completing the study.  
Statistical analysis was undertaken using the SPSS statistical software (version 22; Chicago, Illinois, 
USA) with P < 0.05 taken as being significant. Prior to analysis all datasets were checked for 
normality via visual inspection of normal Q-Q Plots. Outliers were identified by analysis of normal Q-
Q Plots and variance in values greater than +/- two standard deviations. 
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Two-factor repeated measures ANOVA was used to determine the independent and interactive impact 
of time and treatment on the outcome measures. Assumptions of sphericity were assessed via 
Mauchly’s Test of Sphericity.  In cases where the assumptions of sphericity were not met a 
Greenhouse-Geisser correction was applied. When significance was reached subsequent post-hoc 
analysis was undertaken to assess the significance of treatment group effect on the changes from 
baseline (4h-0h) using repeated measure ANOVA and Bonferroni adjustment. Pearson’s correlation 
analysis was used to establish the association between AIx responses and oxylipin levels.  
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RESULTS 
Twenty six individuals with a mean age of 45  5 y and BMI of 27.4  3.3 kg/m2 completed all three 
arms of the trial (Table 1).  The DHA-rich or EPA-rich interventions had no significant effect on BP, 
PWV, RHI or RHI in response to sub-lingual GTN administration (400mg) (Table 2). For AIx, there 
was a statistically significant time (0 h versus 4 h) effect (P < 0.010) and time*treatment interaction (P 
= 0.005) (Figure 1) and post-hoc analysis revealed significant (13.3%, P = 0.047) and borderline 
significant (11.3%, P = 0.06) change scores for the DRO- and the ERO- meal compared to control. No 
time*treatment interactions were evident for TG, NEFA or glucose (P = 0.36, 0.90 and 0.49 
respectively). However time effects were observed with 40% (P < 0.001) and 15% (P = 0.02) higher 
TG and NEFA respectively and 9% lower glucose (P < 0.001) levels at 4 h for all treatment groups 
combined (Table 3). No impact of time or treatment was evident for nitrite or H2S concentrations. 
The ERO- and DRO-meals increased plasma EPA and DHA by 158% (P = 0.03) and 88% (P = 0.05) 
respectively. Post-hoc analysis showed no significant change in DPA in response to any of the meals 
after a Bonferonni correction was applied (Table 4). A total of 7 EPA and DHA hydroxy, epoxide and 
diols metabolites were quantified (Table 4). The ERO-meal significantly increased plasma 
concentrations of 15S-HEPE, 14,15-EpETE, 17,18-EpETE, 14,15-DiHETE, and 17,18-DiHETE with 
the DRO also increasing concentrations of the EPA-derived metabolites 14,15-DiHETE, 17,18-
EpETE, 17,18-DiHETE and the DHA-derived metabolite 19,20-DiHDPA. No changes were evident 
following consumption of the control meal. 
14,15-DiHETE, 17, 18-DiHETE and 19, 20-DiHDPA were significantly negatively correlated with 
AIx (r = -0.215, P = 0.007; r = -0.223, P = 0.005 and r = -0.199, P  = 0.013,  respectively) 
(Supplementary Table 5S) with the AIx absolute response to DHA correlated with baseline AIx 
values (r = -0.413, P = 0.036).  
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DISCUSSION 
Arterial stiffness and vasodilation of the conduit arteries are important determinants of SBP, left 
ventricular hypertrophy and overall CVD risk and are highly prognostic of future cardiovascular 
events (28, 29). Specifically AIx, a measure of pulse wave reflections influenced by vascular smooth 
muscle tone, affects central BP, with a reported HR of 1.68 (95% CI 1.02-2.76) for all-cause mortality 
and 1.60 (95% CI 1.07-2.39) for combined CVD end-points for men in the highest vs. lowest AIx 
tertile (30). In line with our recruitment of participants at above average CVD risk, mean baseline AIx 
values of 24.6% were, approximately 30-50% higher than those observed in RCTs which included 
healthy males (31, 32) or in the lowest male CVD risk tertile in the Copenhagen City Heart Study 
(CCHS)(33), and were within the highest risk tertile for CCHS (33). Our main finding is an overall 
treatment effect on AIx, with the modest differences in responses between DHA and EPA intervention 
relative to control, although statistically different, unlikely to be of clinical significance. If sustained, 
the observed DHA mediated 13.3% reduction would equate to a decrease in 10 year CVD risk from 
3.3% to 2.8% in this population, using associations generated by the European Society of Cardiology 
(34). Furthermore EPA and DHA derived epoxides and diols were shown to be highly modifiable in 
the postprandial state and likely to contribute to the observed improved vascular function. 
While to the best of our knowledge no previous RCT has compared the impact of EPA vs. DHA on 
AIx, a limited number of studies have reported a positive impact of chronic and acute combined 
EPA+DHA supplementation on this measure of arterial stiffness (9, 10, 35, 36). Using a comparable 
LCn-3PUFA exposure (4.7g EPA+DHA, EPA:DHA-0.67) Chong et al., reported that the inclusion of 
fish oil in a test meal reduced AIx in the 1.5-4h postprandial period in healthy adults, with an 
improved stiffness index only evident in male participants (9). Purcell et al., observed significant 
reductions in AIx in healthy men after fish oil (5g EPA+DHA, EPA:DHA-1.6) and algal oil (5g DHA 
only) administration, during a 6 h postprandial assessment which were most evident at 2 h and of 
comparable size effect to those observed in the current RCT (10). However, they did not include an 
EPA-only meal which would allow direct comparison of the vasoactivity of EPA vs. DHA on AIx and 
other measures of vascular function (10).  
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In the current study no effect of the EPA- or DHA-meals on PWV or RHI was observed. PWV is a 
proximal measure of gross arterial stiffness determined by the speed at which the pulse wave travels 
through the arterial tree, with an increased speed indicating increased stiffness and overall vascular 
dysfunction (28). In a meta-analysis of 17 studies, an increased PWV was associated with an increased 
risk of total CV events, CV mortality and all-cause mortality (RR (95% CI) of 2.26 (1.89-2.70), 2.02 
(1.68-2.42) and 1.90 (1.61-2.70) respectively) (37). The observed lack of impact of treatment on 
postprandial PWV in the present study corroborates previous observations showing that PWV is not 
acutely modified in response to altered fatty acid composition (38, 39).  
Peripheral arterial tonometry RHI as assessed by the proprietary Endopat device was employed as an 
observer-independent, high-throughput technique to assess endothelium-dependent vasodilation (40). 
Since this study was initiated, concerns have been expressed regarding the sensitivity of the Endopat 
technique, and in particular its ability to assess (subtle changes in) endothelial function in health 
individuals or at the early stages of vascular dysfunction (41, 42). Future trials should employ more 
sensitive techniques such as flow-mediated dilatation, in order to assess the impact of EPA vs. DHA 
on postprandial endothelium-dependent vasodilation. The prognostic value of a compromised flow-
induced vasodilation (43), the observation of improved response to flow following chronic EPA+DHA 
supplementation (3) and of a differential and stronger impact of DHA relative to EPA using a less 
widely used and indirect measure of endothelium-dependent vasodilation, namely systemic vascular 
resistance as measured by the Finometer finger arterial BP monitor (11), provides strong justification 
for such research to be conducted. 
Much of the mechanistic focus centered around the modulation of vascular function by EPA and DHA 
has been on nitric oxide (NO) bioavailability and endothelial NO synthase (eNOS) expression and 
phosphorylation status (44). There has been a degree of inconsistency with regards to the capacity of 
LCn-3PUFA to modify NO production postprandially, with some studies indicating an effect (8), 
whereas others have observed no changes (10). As NO is a labile compound, its status is often 
estimated via the concentrations of its oxidation products, most notably nitrite and nitrate, with nitrite 
thought to be the most reflective of changes in NO concentration (45). In agreement with previous 
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investigations utilizing this method there was no evidence of postprandial EPA or DHA mediated 
changes in plasma levels of nitrite or total NO metabolites(10). 
H2S has recently emerged as a novel endothelium derived regulator of vascular function (16, 46). 
Although, the impact of EPA and DHA on H2S status in the vasculature is almost completely 
unknown, a recent study reported an activation of cystathionine-γ-lyase (CSE), the main H2S 
biosynthesis enzyme, in response to DHA-rich tuna-oil supplementation in the lung tissue of Sprague-
Dawley rats (47). However no EPA or DHA mediated differences were evident in the current RCT 
and it is unlikely H2S contributes to reduced arterial stiffness associate with acute DHA consumption.   
Finally, our study was novel in its investigation of the impact of EPA vs. DHA on the plasma 
concentration of selected vasoactive cytochrome 450 enzyme-derived EPA and DHA metabolites 
(oxylipins) and for the first time concurrent assessment of the impact of LCn-3PUFA on the 
vasoactive oxylipin profile and vascular responses in humans was conducted. Previous in vitro, ex vivo 
and animal investigations have shown that the LCn-3PUFA epoxides are particularly potent, and that 
the DHA epoxides account for approximately 75% of DHA’s capacity to illicit vasodilation in in-vitro 
models (48). Furthermore, the DHA epoxides have emerged as being more vasoactive than their EPA 
counterparts (15, 48, 49). In 2010, Shearer et al., reported for the first time the presence of EPA- and 
DHA- derived epoxide and diols in human plasma and their modulation by EPA plus DHA 
supplementation (50), which has been subsequently corroborated (51, 52). Consistent with the only 
previous acute assessment (52), which used a supra-physiological DHA-rich fish oil dose (26g 
EPA+DHA, EPA:DHA- 0.12), it can be confirmed that the hydroxy, epoxide and diol oxylipins are 
highly modifiable in the postprandial state with several fold higher concentration evident at 4 h post 
consumption of test meals containing 4.16g of EPA or DHA.  
The DHA derived diol 19,20 EpDPE has emerged as a potentially potent vasomodulator with direct 
effects on vascular smooth muscle tone (48). A limitation of this study is that we were not able to 
detect the 19,20 EpDPE which fell below the limit of detection. Results from the human serum 
metabolome project suggest that the molar ratio of 19,20 EpDPE to 19,20 DiHDPA is in the range of 1 
in 8 (53), which places plasma concentrations of 19,20 EpDPE in the low picomolar range. However, 
we did observe a highly significant 1.3 fold increase in the daughter 19,20 DiHDPA diol in response 
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to DHA consumption, with 19,20 DiHDPA concentration negatively correlated with AIx responses. 
Given that 19,20 DiHDPA is directly and exclusively derived from 19,20EpDPE via the activity of the 
soluble epoxide hydrolase, the higher postprandial 19,20 DiHDPA levels are likely reflective of 
increases in 19,20 EpDPE which is proposed to have contributed to the vascular impact of DHA vs. 
EPA.  
However, we cannot preclude the possibility that EPA-derived oxylipins also contributed to the 
vascular response following DRO intervention. The strong trend towards an increase in plasma EPA 
following DRO intervention, was likely due to some EPA being provided as part of the DRO 
intervention or the known tissue retroconversion of DHA to EPA (54). These sources provided 
sufficient amounts for the CYP epoxygenases that generally prefer EPA over DHA and arachidonic 
acid (55) with the DRO meal resulting in an increase in three EPA-derived oxylipin metabolites, with 
14,15-DiHETE and 17, 18-DiHETE correlated with AIx. In addition to the CYP derived oxylipins, 
prostanoids and lipoxygenase derived resolvins may contribute to the vascular response to n-3 PUFA 
intervention. Although potentially important in the vascular wall, this latter group of compounds have 
proved difficult to quantify in the human circulation.  
Therefore following DHA intervention changes in the tissues status of both DHA and EPA and their 
associated oxylipins and other metabolites may act in a complementary and additive fashion (56) to 
mediate the impact on vascular function. 
The strengths of the current study were its cross-over design, its inclusion of a range of measures of 
vascular function, with simultaneous analysis of vascular function and potential lipid and non-lipid 
derived mediators in the circulation at the clinical assessment time-points. A limitation is the likely 
lack of sensitivity of the Endopat technique employed to assess the impact of treatment of endothelial 
dependent vasodilatation.   
In summary, the results of this study show that DHA improves postprandial vascular function, with an 
effect size which would translate into a meaningful reduction in CVD risk, with a strong trend also 
evident following EPA intervention. The targeted lipidomic profiling indicates that postprandial 
changes in the LCn-3PUFA epoxides and diol occur and are likely to play a mechanistic role as 
effector molecules of these changes in vascular tone. Further research is needed to fully establish the 
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individual impact of EPA vs. DHA on clinical endpoint and disease biomarkers and to gain insight 
into the bioactive lipids modulating the effects. Ultimately such information would allow, the 
refinement of current EPA and DHA recommendations, the development of fish oil blends (with 
defined EPA and DHA content) to suit phenotype, and would inform the design of much needed non-
marine sources of these fatty acids.  
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FIGURE LEGENDS  
Figure 1.  Augmentation index (%) at baseline and in response to treatment.  
Data are presented as mean ± SEM (n = 26). CO: Control oil; ERO: EPA rich oil; DRO: DHA rich oil. 
Two-factor repeated measures ANOVA. P, time < 0.010, P, time*treatment = 0.005. * indicates 
significantly different (P = 0.047) change scores for DRO when compared to CO.   
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TABLES 
 
Table 1. Study population characteristics (n=26).  
Characteristic                                 Value 
Age (years) 
Weight (kg) 
BMI (kg/m2) 
Waist circumference (cm) 
Total cholesterol (mmol/L) 
HDL-cholesterol (mmol/L) 
Systolic Blood pressure (mmHg) 
Diastolic Blood pressure (mmHg) 
45 ± 5 (36 - 54) 
87.0 ± 11.5 (73.5-129.4) 
27.4 ± 3.3 (20.4-39.9) 
95.5 ± 10.4 (76.8-128.0) 
5.8 ± 0.9 (3.8-7.3) 
1.4 ± 0.3 (0.86-2.32) 
136 ± 10 (101-150) 
86 ± 7 (67.3-104) 
Data are presented as mean ± SEM with the range of values in brackets. 
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Table 2. Vascular measurements at baseline (0h) and in response to treatment (4h). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are presented as mean ± SEM (n=26). CO: Control oil; ERO: EPA- rich oil; DRO: DHA- rich oil; DBP: diastolic blood pressure; SBP: 
systolic blood pressure; RHI: reactive hyperaemic index; RHI*GTN: RHI after 400mg of sub-lingual nitroglycerine (GTN); PWV: pulse 
wave velocity. 1Two-factor repeated measures ANOVA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CO meal   ERO-meal DRO-meal P, time1 P, time*treatment1 
 
   (0h) (4h)   (0h) (4h) (0h) (4h)  
 
 
DBP (mmHg) 
 
77 ± 1 
 
74 ± 2 
 
77 ± 2 
 
76 ± 2 
 
75 ± 1 
 
76 ± 1 
 
0.25 0.15 
SBP (mmHg) 
 
125 ± 3 
 
      125 ± 2 
 
127 ± 2 
 
128 ± 2 
 
125 ± 2 
 
124 ± 1 
 
0.93 0.38 
RHI  2.4 ± 0.1 
 
  2.4 ± 0.1 
 
2.4 ± 0.1 
 
2.5 ± 0.1 
 
2.4 ± 0.1 
 
2.4 ± 0.1 
 
0.75 0.92 
RHI*GTN -   1.7 ± 0.1 - 1.5 ± 0.1 - 1.6 ± 0.1 - 0.59 
PWV (m/s) 
 
8.5 ± 0.2 
 
  8.3 ± 0.2 8.3 ± 0.1 
 
8.4 ± 0.2 
 
8.2 ± 0.2 
 
8.2 ± 0.2 
 
0.85 0.32 
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 Table 3. Biochemical measures at baseline and in response to treatment. 
 
Data are presented as mean ± SEM (n=26). CO: Control oil; ERO: EPA- rich oil; DRO: DHA- rich oil; H2S: hydrogen sulfide. 1Two-factor repeated measures 
ANOVA. 
 
 
 
 
 
 
 
 
 
 
 
                 CO meal                 ERO-meal     DRO-meal   P, time1 P, time*treatment1 
 
  (0h)        (4h)          (0h)        (4h)     (0h)          (4h)  
 
 
Triglycerides (mmol/L) 
 
1.7 ± 0.1 
 
2.5 ± 0.2 
 
1.6 ± 0.1 
 
    2.3 ± 0.2 
 
 1.6 ± 0.1 
 
2.2 ± 0.1 
 
<0.001      0.36 
NEFA (μmol/L) 
 
359 ± 24 
 
   424 ± 36 
 
    335 ± 32 
 
   384 ± 35 
 
    351 ± 31 
 
     398 ± 33 
 
0.020      0.90 
Glucose (mmol/L) 5.2 ± 0.1 
 
4.7 ± 0.1 
 
5.2 ± 0.1 
 
    4.7 ± 0.1 
 
 5.2 ± 0.1 
 
 4.9 ± 0.1 
 
<0.001      0.49 
Nitrite (mmol/L) 
 
 88.7 ± 8.6 
 
80.1 ± 7.2    84.3 ± 6.2   74.3 ± 6.5 78.4 ± 6.5 
 
        81.9 ± 0.1 0.37      0.46 
H2S (mmol/L) 
 
 348.3 ± 59.3 
 
386.6 ± 62.0  369.2 ± 59.6 
 
341.7 ± 39.4 
 
377.5 ± 63.6 
 
   386.4 ± 61.1   
 
0.76      0.35 
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Table 4. Plasma long chain n-3 PUFA concentrations along with select hydroxy, epoxide and diol metabolites, measured at baseline and in response to 
treatment (4h).  
Data are presented as mean ± SEM (n=26). ERO- EPA rich oil, DRO- DHA rich oil. 1Two-factor repeated measures ANOVA. *Indicates a significant 
difference (Pin change from baseline when compared to control.  
 
 
 
 
 
 Control meal ERO-meal DRO-meal 
 
   P, time1     P, time*treatment1 
 (0h)      (4h) (0h)     (4h) (0h)     (4h)   
Fatty acids (mg/ml)         
EPA 3.0  0.1 3.5  0.1  3.3  0.1   8.5  0.3* 3.7  0.1 5.1  0.1 <0.001 0.49 
DPA  0.9  0.1 1.0  0.1 1.1  0.1 0.7  0.1 0.8  0.1 0.9  0.1 0.86 0.02 
DHA 6.6  0.2  6.4  0.1 6.7  0.2 7.5  0.2 6.4  0.2 12.0  0.3* 0.007 0.006 
         
Oxylipins (ng/ml)         
Hydroxy Metabolites         
15S-HEPE  0.2 ± 0.1 0.1 ± 0.0 0.8 ± 0.5   2.6 ± 0.7* 0.4 ± 0.2 0.9 ± 0.3 0.05 0.03 
18S-HEPE 
 
0.5 ± 0.2 0.2 ± 0.1 1.8 ± 1.0 6.5 ± 2.3 0.5 ± 0.3 3.8 ± 1.6 0.02 0.07 
Epoxide Metabolites         
14, 15-EpETE  0.6 ± 0.3 0.0 ± 0.0 0.4 ± 0.3 2.9 ± 0.8* 0.4 ± 0.2 0.5 ± 0.1 0.06 0.001 
17, 18-EpETE 
 
0.9 ± 0.5 0.4 ± 0.0 0.6 ± 0.2 9.9 ± 1.8* 0.8 ± 0.3 2.6 ± 0.4* <0.001 <0.001 
Diol Metabolites         
14, 15-DiHETE 1.5 ± 0.1 1.5 ± 0.0 1.7 ± 0.1 3.2 ± 0.3* 1.6 ± 0.0 2.2 ± 0.1* <0.001 <0.001 
17, 18-DiHETE 3.0 ± 0.5 2.6 ± 0.2 2.9 ± 0.3 9.7 ± 1.0* 2.8 ± 0.2 6.0 ± 0.4* <0.001 <0.001 
19, 20-DiHDPA 0.9 ± 0.1 1.1 ± 0.1 0.8 ± 0.1   1.3 ± 0.1 0.9 ± 0.1 2.1 ± 0.2* <0.001 <0.001 
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